

Form PTO-1449 (Modified)	FEB 19 2003	U.S. Department of Commerce Patent and Trademark Office	Serial No. 10/045,884	Group Art Unit 1617	Filing Date 01/09/02	Atty. Docket No. Le A 34 992
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION			Applicant(s) Fahrig, et al.			

U.S. PATENT DOCUMENTS										
*		DOCUMENT NO.				DATE MM/DD/YY	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS													
		DOCUMENT NO.						DATE DD/MM/YY	COUNTRY	PRIMARY CLASS	SUB- CLASS	TRANSLATION	
												YES	NO
<i>SV</i>	F4	9	9	2	9	3	4	6	17/06/99	WO	A61K 45/06		
											RECEIVED		
											FEB 26 2003		
											TECH CENTER 1600/2900		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)										
<i>SV</i>	R4	Abstract XP-002221547, various, Merck Manual, pgs. 1466-1467 (1999)								
<i>SV</i>	R5	Kukley, M., Schaper, C., Becker, A., Rose, K., Kriegstein, J., "Effect of 5-Hydroxytryptamine 1A Receptor Agonist Bay X 3702 on BCL-2 and Bax Proteins Level in the Ipsilateral Cerebral Cortex of Rats After Transient Focal Ischaemia", Neuroscience, 107: 405-413 (2001)								
<i>SV</i>	R6	Sernkova, I., Wolz, P., Kriegstein, J., "Neuroprotective Effect of 5-HT _{1A} Receptor Agonist, Bay X 3702, Demonstrated in Vitro and in Vivo", Eu. J. of Pharmacology, 359: 251-260 (1998)								
<i>SV</i>	R7	Kline, A., Yu, J., Horvath, E., Marion, D., Dixon, C., "The Selective 5-HT _{1A} Receptor Agonist Repinotan HCL Attenuates Histopathology and Spatial Learning Deficits Following Traumatic Brain Injury in Rats", Neuroscience, 106: 547-555 (2001)								

EXAMINER <i>G. V -</i>	DATE CONSIDERED <i>5/30/03</i>
* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	